135 related articles for article (PubMed ID: 30116431)
21. Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
Pariente A; Arpurt JP; Rémy AJ; Rosa-Hézode I; Causse X; Heluwaert F; Macaigne G; Henrion J; Renou C; Schnee M; Salloum H; Hommel S; Pilette C; Arotcarena R; Barjonet G; Lison H; Bourhis F; Jouannaud V; Pauwels A; Le eaBricquir Y; Geagea E; Condat B; Ripault MP; Zanditenas D; de Montigny-Lenhardt S; Labadie H; Tissot B; Maringe E; Cadranel JF; Hagège H; Lesgourgues B;
Presse Med; 2019 Mar; 48(3 Pt 1):e101-e110. PubMed ID: 30853287
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
23. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
[TBL] [Abstract][Full Text] [Related]
24. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.
Fox DS; McGinnis JJ; Tonnu-Mihara IQ; McCombs JS
J Gastroenterol Hepatol; 2017 Jun; 32(6):1136-1142. PubMed ID: 27869323
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
[TBL] [Abstract][Full Text] [Related]
26. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
27. Treatment of hepatitis C: Results in real life.
Hézode C
Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
[TBL] [Abstract][Full Text] [Related]
29. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
[TBL] [Abstract][Full Text] [Related]
30. Rapid virologic response in chronic hepatitis C genotype 1: Evaluation of pretreatment factors in patients.
Turken M; Kose S; Colak Ergun N; Tatar B
Arab J Gastroenterol; 2020 Dec; 21(4):278-281. PubMed ID: 32830089
[TBL] [Abstract][Full Text] [Related]
31. Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation.
Wu SH; Loong CC; Chu CJ; Su CW; Lin CC; Hsia CY; Liu C; Lee SD; Wang YJ; Lee FY; Linb NC; Chen CY; Huang YH; Hou MC
J Chin Med Assoc; 2020 Jan; 83(1):18-24. PubMed ID: 31714442
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
33. A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin.
Wu SH; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2019 Mar; 82(3):186-190. PubMed ID: 30908411
[TBL] [Abstract][Full Text] [Related]
34. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis.
Shah I; Ahmad W; Qadir A; Muhammad I; Islam M; Shah M; Jan N; Anjum S
Cureus; 2021 Nov; 13(11):e19768. PubMed ID: 34950547
[TBL] [Abstract][Full Text] [Related]
37. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
[TBL] [Abstract][Full Text] [Related]
39. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
[TBL] [Abstract][Full Text] [Related]
40. 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant.
Fabrizi F; Alonso C; Palazzo A; Anders M; Reggiardo MV; Cheinquer H; Zuain MGV; Figueroa S; Mendizabal M; Silva M; Ridruejo E;
Ann Hepatol; 2021; 25():100337. PubMed ID: 33684523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
